Cargando…

Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients

BACKGROUND: The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher wheth...

Descripción completa

Detalles Bibliográficos
Autores principales: Gibot, Sébastien, Lafon, Thomas, Jacquin, Laurent, Lefevre, Benjamin, Kimmoun, Antoine, Guillaumot, Anne, Losser, Marie-Reine, Douplat, Marion, Argaud, Laurent, De Ciancio, Guillaume, Jolly, Lucie, Touly, Nina, Derive, Marc, Malaplate, Catherine, Luc, Amandine, Baumann, Cédric, François, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423708/
https://www.ncbi.nlm.nih.gov/pubmed/37574520
http://dx.doi.org/10.1186/s40635-023-00532-4
_version_ 1785089509730287616
author Gibot, Sébastien
Lafon, Thomas
Jacquin, Laurent
Lefevre, Benjamin
Kimmoun, Antoine
Guillaumot, Anne
Losser, Marie-Reine
Douplat, Marion
Argaud, Laurent
De Ciancio, Guillaume
Jolly, Lucie
Touly, Nina
Derive, Marc
Malaplate, Catherine
Luc, Amandine
Baumann, Cédric
François, Bruno
author_facet Gibot, Sébastien
Lafon, Thomas
Jacquin, Laurent
Lefevre, Benjamin
Kimmoun, Antoine
Guillaumot, Anne
Losser, Marie-Reine
Douplat, Marion
Argaud, Laurent
De Ciancio, Guillaume
Jolly, Lucie
Touly, Nina
Derive, Marc
Malaplate, Catherine
Luc, Amandine
Baumann, Cédric
François, Bruno
author_sort Gibot, Sébastien
collection PubMed
description BACKGROUND: The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher whether plasma concentration of the soluble form of TREM-1 (sTREM-1) could predict the outcome of hospitalized COVID-19 patients. METHODS: We conducted a multicentre prospective observational study in 3 university hospitals in France. Consecutive hospitalized patients with confirmed infection with SARS-CoV-2 were enrolled. Plasma concentration of sTREM-1 was measured on admission and then at days 4, 6, 8, 14, 21, and 28 in patients admitted into an ICU (ICU cohort: ICUC) or 3 times a week for patients hospitalized in a medical ward (Conventional Cohort: ConvC). Clinical and biological data were prospectively recorded and patients were followed-up for 90 days. For medical ward patients, the outcome was deemed complicated in case of requirement of increased oxygen supply > 5 L/min, transfer to an ICU, or death. For Intensive Care Unit (ICU) patients, complicated outcome was defined by death in the ICU. RESULTS: Plasma concentration of sTREM-1 at inclusion was higher in ICU patients (n = 269) than in medical ward patients (n = 562) (224 pg/mL (IQR 144–320) vs 147 pg/mL (76–249), p < 0.0001), and higher in patients with a complicated outcome in both cohorts: 178 (94–300) vs 135 pg/mL (70–220), p < 0.0001 in the ward patients, and 342 (288–532) vs 206 pg/mL (134–291), p < 0.0001 in the ICU patients. Elevated sTREM-1 baseline concentration was an independent predictor of complicated outcomes (Hazard Ratio (HR) = 1.5 (1.1–2.1), p = 0.02 in ward patients; HR = 3.8 (1.8–8.0), p = 0.0003 in ICU patients). An sTREM-1 plasma concentration of 224 pg/mL had a sensitivity of 42%, and a specificity of 76% in the ConvC for complicated outcome. In the ICUC, a 287 pg/mL cutoff had a sensitivity of 78%, and a specificity of 74% for death. The sTREM-1 concentrations increased over time in the ConvC patients with a complicated outcome (p = 0.017), but not in the ICUC patients. CONCLUSIONS: In COVID-19 patients, plasma concentration of sTREM-1 is an independent predictor of the outcome, although its positive and negative likelihood ratio are not good enough to guide clinical decision as a standalone marker. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40635-023-00532-4.
format Online
Article
Text
id pubmed-10423708
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-104237082023-08-15 Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients Gibot, Sébastien Lafon, Thomas Jacquin, Laurent Lefevre, Benjamin Kimmoun, Antoine Guillaumot, Anne Losser, Marie-Reine Douplat, Marion Argaud, Laurent De Ciancio, Guillaume Jolly, Lucie Touly, Nina Derive, Marc Malaplate, Catherine Luc, Amandine Baumann, Cédric François, Bruno Intensive Care Med Exp Research Articles BACKGROUND: The immuno-receptor Triggering Expressed on Myeloid cells-1 (TREM-1) is activated during bacterial infectious diseases, where it amplifies the inflammatory response. Small studies suggest that TREM-1 could be involved in viral infections, including COVID-19. We here aim to decipher whether plasma concentration of the soluble form of TREM-1 (sTREM-1) could predict the outcome of hospitalized COVID-19 patients. METHODS: We conducted a multicentre prospective observational study in 3 university hospitals in France. Consecutive hospitalized patients with confirmed infection with SARS-CoV-2 were enrolled. Plasma concentration of sTREM-1 was measured on admission and then at days 4, 6, 8, 14, 21, and 28 in patients admitted into an ICU (ICU cohort: ICUC) or 3 times a week for patients hospitalized in a medical ward (Conventional Cohort: ConvC). Clinical and biological data were prospectively recorded and patients were followed-up for 90 days. For medical ward patients, the outcome was deemed complicated in case of requirement of increased oxygen supply > 5 L/min, transfer to an ICU, or death. For Intensive Care Unit (ICU) patients, complicated outcome was defined by death in the ICU. RESULTS: Plasma concentration of sTREM-1 at inclusion was higher in ICU patients (n = 269) than in medical ward patients (n = 562) (224 pg/mL (IQR 144–320) vs 147 pg/mL (76–249), p < 0.0001), and higher in patients with a complicated outcome in both cohorts: 178 (94–300) vs 135 pg/mL (70–220), p < 0.0001 in the ward patients, and 342 (288–532) vs 206 pg/mL (134–291), p < 0.0001 in the ICU patients. Elevated sTREM-1 baseline concentration was an independent predictor of complicated outcomes (Hazard Ratio (HR) = 1.5 (1.1–2.1), p = 0.02 in ward patients; HR = 3.8 (1.8–8.0), p = 0.0003 in ICU patients). An sTREM-1 plasma concentration of 224 pg/mL had a sensitivity of 42%, and a specificity of 76% in the ConvC for complicated outcome. In the ICUC, a 287 pg/mL cutoff had a sensitivity of 78%, and a specificity of 74% for death. The sTREM-1 concentrations increased over time in the ConvC patients with a complicated outcome (p = 0.017), but not in the ICUC patients. CONCLUSIONS: In COVID-19 patients, plasma concentration of sTREM-1 is an independent predictor of the outcome, although its positive and negative likelihood ratio are not good enough to guide clinical decision as a standalone marker. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s40635-023-00532-4. Springer International Publishing 2023-08-14 /pmc/articles/PMC10423708/ /pubmed/37574520 http://dx.doi.org/10.1186/s40635-023-00532-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research Articles
Gibot, Sébastien
Lafon, Thomas
Jacquin, Laurent
Lefevre, Benjamin
Kimmoun, Antoine
Guillaumot, Anne
Losser, Marie-Reine
Douplat, Marion
Argaud, Laurent
De Ciancio, Guillaume
Jolly, Lucie
Touly, Nina
Derive, Marc
Malaplate, Catherine
Luc, Amandine
Baumann, Cédric
François, Bruno
Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
title Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
title_full Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
title_fullStr Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
title_full_unstemmed Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
title_short Soluble TREM-1 plasma concentration predicts poor outcome in COVID-19 patients
title_sort soluble trem-1 plasma concentration predicts poor outcome in covid-19 patients
topic Research Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423708/
https://www.ncbi.nlm.nih.gov/pubmed/37574520
http://dx.doi.org/10.1186/s40635-023-00532-4
work_keys_str_mv AT gibotsebastien solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT lafonthomas solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT jacquinlaurent solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT lefevrebenjamin solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT kimmounantoine solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT guillaumotanne solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT lossermariereine solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT douplatmarion solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT argaudlaurent solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT deciancioguillaume solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT jollylucie solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT toulynina solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT derivemarc solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT malaplatecatherine solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT lucamandine solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT baumanncedric solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients
AT francoisbruno solubletrem1plasmaconcentrationpredictspooroutcomeincovid19patients